HK Stock Market Move | InnoCare Pharma (09969) rose by over 3% after the performance report. Net profit attributable to the parent for the first quarter increased by 488.93% year-on-year, achieving a milestone with Zenas.

InnoCare Pharma (09969) rose more than 3% after the performance, up 2.63% as of the press release, at HK$14.44, with a turnover of HK$27.966 million. On the news front, on April 23, InnoCare Pharma released its first quarter report for 2026. The group achieved operating income of 529 million yuan, a year-on-year increase of 38.65%; net profit attributable to shareholders of listed companies was 106 million yuan, a year-on-year increase of 488.93%; basic earnings per share were 0.06 yuan. From January to March 2026, the company's pharmaceutical sales revenue was 450 million yuan, a year-on-year increase of 44.54% compared to the same period last year, with total operating income of 529 million yuan, an increase of 38.65% year-on-year. The main reasons for the increase in operating income were the continued increase in sales of the core product Ibiptinib, the additional contribution of Tuxemab and Zolquimtinib, and the completion of milestone deliveries following the licensing agreement with Zenas BioPharma, Inc. ("Zenas"). The company's net profit for the first quarter of 2026 was 102 million yuan, an increase of 607.72% compared to the same period last year. The company's commercialization system is mature, the research and development pipeline is progressing smoothly, and it will maintain high-quality growth in the future.